Anemia, Cancer
Conditions
Brief summary
The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies). Transfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management. Recommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice.
Interventions
OTHERanemia assessment
evaluation of anemia status
Sponsors
Weprom
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years old, * Follow-up for cancer justifying hospitalization, * Presenting anemia defined by a hemoglobin level \<11 g / dL, * Patient not having objected to the collection of his data after oral and written information.
Exclusion criteria
* patients with a hemoglobin level ≥ 11 g / dL, * adult patients under guardianship, curatorship or deprived of liberty, * pregnancy or breast-feeding in progress at the time of hospitalization.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of anemia | 2 years | number of patient with anemia (\<11.0 g/dL) upon admission to hospital on the number of patients hospitalized over the period |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of transfusion prescriptions | 2 years | number of transfusions performed on the number of patients hospitalized over the period |
| Assessment of erythropoiesis stimulating agents (EPO) prescriptions | 2 years | number of prescriptions for erythropoiesis stimulating agents (EPO) |
| Assessment of iron prescriptions | 2 years | number of prescriptions of iron (oral and intravenous) |
| Time between last transfusion and date of death | 2 years | Delay between the date of the last transfusion and the date of patient's death |
| overall survival | 2 years | Delay between the enrollment date and the date of patient's death |
Countries
France
Outcome results
None listed